Introduction {#s1}
============

Tuberculosis (TB) remains the leading cause of mortality by a single infectious agent, accounting for an estimated 1.6 million deaths worldwide. According to the latest report by the World Health Organization 10 million people are estimated to have developed TB disease in 2017 ([@B1]). However, the majority of individuals infected with *Mycobacterium tuberculosis* are asymptomatic and remain in a latent stage of infection. Data on infected individuals is not included in the World Health Organization TB report as TB infection is not a notifiable disease. Therefore, only estimates exist with one of the most recent estimates suggesting that in 2014 a total of 1.7 billion individuals, equivalent to 23% of the global population, had latent TB infection ([@B2]).

Progression from latent TB infection to active TB disease occurs in approximately one in ten adults. Children, however, progress more frequently to active TB and progression may be particularly rapid in the first 2 years of life ([@B3]--[@B5]). Early diagnosis and treatment are therefore key to reduce the burden of active TB in children.

Immuno-diagnostic tests are the main tools for the diagnosis of latent TB infection and both the tuberculin skin test (TST) and interferon-gamma release assays (IGRA) are used in the clinical setting ([@B6], [@B7]). The latter have been developed to overcome the limited specificity of the TST ([@B8], [@B9]). In adults the two commercially available IGRA, the QuantiFERON-TB and T-SPOT.TB---both existing in several test generations---have replaced the TST in many settings, primarily in an attempt to improve specificity ([@B10]).

In children, there is evidence that IGRA may have limited sensitivity and therefore the TST is still advocated by most experts ([@B11]--[@B14]). In addition, indeterminate IGRA results---due to either high interferon-γ background concentration in the negative control or low interferon-γ response in the positive control---have been shown to be more frequent in children compared to adults ([@B15]--[@B18]).

Underlying reasons for higher proportions of indeterminate IGRA results in children are largely speculative, but several contributing factors including age, concomitant infections and malnutrition have been postulated ([@B18]--[@B20]).

The aim of this study was to summarize the existing data on indeterminate IGRA results in children and determine key influencing variables.

Methods {#s2}
=======

Study Selection
---------------

A systematic literature search of studies reporting IGRA results in children was performed using PubMed, Embase, and Web of Science. Studies published until October 1st, 2018 were considered. The study was done according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement ([@B21]) ([Supplementary Material](#SM1){ref-type="supplementary-material"} 1 PRISMA Checklist). The following search terms were used: (tuberculosis OR TB) AND \[(((t-spot.tb) OR t-spot) OR quantiferon-tb) OR quantiferon\] AND (children OR pediatric OR pediatric). The following inclusion criteria were used (i) patients in the pediatric age range with a mean or median age \<18 years and a maximum upper age range of 24 years, (ii) results of at least one of the commercially available IGRA detailed (including a statement about indeterminate test results), (iii) publication in English, French, or German. Case reports, case series, conference abstracts and studies involving fewer than 10 participants, commentaries and reviews were excluded. The search and selection of included studies was done by MG, NM, and NR. In unclear cases a joint decision for inclusion or exclusion of the study was made.

Data Extraction
---------------

Data were extracted using a standard form including the following variables: year of publication, country in which the study was done, number of participants, mean or median age of participants, age range of participants, type of test performed, number of positive, negative and indeterminate results, definition of indeterminate result, Bacillus Calmette-Guérin (BCG) vaccination status, human immunodeficiency virus (HIV) infection status and information on other potential immunocompromising conditions (e.g., rheumatic diseases, cancer) and concomitant infections (e.g., helminth or other parasitic infections).

Statistical Analysis
--------------------

The primary outcome was the proportion of indeterminate IGRA results, which was calculated as the number of indeterminate test results divided by the total number of valid test results. Stratified meta-analyses for proportions were performed using a random effects model and the DerSimonian and Laird method, with the estimate of heterogeneity taken from the inverse-variance fixed-effect model. Stratification variables comprised type of IGRA used (QuantiFERON-TB and T-SPOT.TB), age groups (0--7 ≥ 8 years), geographical location of the population under study (Africa, Australia, North America, South America, Asia, Europe) and immune status (HIV infection rate groups, and presence of other immunocompromising factors). Heterogeneity was determined using the I^2^ statistic.

In studies comparing both QuantiFERON-TB and T-SPOT.TB, additional stratified meta-analyses for risk differences were performed. Risk differences were defined as the difference in the proportion of indeterminate results between the two IGRA tests and were calculated according to Newcombe and Altman ([@B22]). For comparison of pooled risk difference, we applied the DerSimonian and Laird risk difference method. Study weight was indicated by using random effect models for the individual studies to account for the different study characteristics. For risk difference analysis stratification for age groups were done in two groups (0--7 ≥ 8 years) because of the limited number of available datasets.

To further explore potential sources of heterogeneity, we used meta-regression if I^2^ was higher than 30%. We considered the following variables as potentially explanatory in a multivariable model: type of IGRA used, age group, geographic location of the population under study, immune status (HIV or other immunocompromising conditions) were considered as explanatory variables in a multivariable model.

We used GraphPad Prism Version 7.02 (GraphPad Software, San Diego, CA, USA) and Stata Version 15.1 (StataCorp, College Station, TX, USA) to generate figures and perform meta-analyses. We reported estimated effect sizes with corresponding 95% confidence intervals (95% CI). A *p* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Demographical Data of the Studies Included
------------------------------------------

A total of 1,293 citations were identified, of which 379 publications were eligible for full-text assessment and 133 (5 of which were found through additional sources) were included in the final analysis ([Figure 1](#F1){ref-type="fig"}). As 21 publications included data on both QuantiFERON-TB and T-SPOT.TB and one study included data on two different QuantiFERON-TB tests a total of 155 datasets were generated. [Table 1](#T1){ref-type="table"} provides an overview of the studies included and summarizes their key characteristics.
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###### 

Study results and characteristics of all included papers, sorted by year of publication.

  **Study number**   **Authors**                          **Year of publication**   **Country**                          **IGRA**            **Participants n**   **Positive results n**   **Negative results n**   **Indeterminate results n**   **Proportion of ind. %**   **Mean age years**   **Median age years**   **Age range years**   **Years study performed**   **BCG vaccinated n (%)**   **HIV positive n (%)**   **Other immunodeficiency**                                             **Other immunodeficiency (%)**
  ------------------ ------------------------------------ ------------------------- ------------------------------------ ------------------- -------------------- ------------------------ ------------------------ ----------------------------- -------------------------- -------------------- ---------------------- --------------------- --------------------------- -------------------------- ------------------------ ---------------------------------------------------------------------- --------------------------------
  1                  Connell et al. ([@B23])              2006                      Australia                            QFT Gold            101                  20                       64                       17                            16.8%                      ns                   ns                     0.4--17.9             2004--2005                  52.5%                      ns                       ns                                                                     ns
  2                  Dogra et al. ([@B24])                2007                      India                                QFT Gold            105                  11                       94                       0                             0%                         ns                   6                      1--12                 2004--2005                  81.9%                      ns                       ns                                                                     ns
  3a                 Domínguez et al. ([@B25])            2008                      Spain                                QFT-GIT             134                  50                       84                       0                             0%                         ns%                  ns                     0--18                 2004--2006                  64.2%                      0%                       ns                                                                     ns
  3b                 Domínguez et al. ([@B25])            2008                      Spain                                T-SPOT.TB           134                  51                       80                       3                             2.2%                       ns%                  ns                     0--18                 2004--2006                  64.2%                      0%                       ns                                                                     ns
  4                  Taylor et al. ([@B26])               2008                      UK                                   QFT                 120                  6                        107                      7                             5.8%                       10%                  ns                     0.3--16               2004--2005                  46.7%                      ns                       ns                                                                     ns
  5                  Okada et al. ([@B27])                2008                      Cambodia                             QFT Gold            204                  33                       162                      9                             4.4%                       ns%                  ns                     0--5                  2005                        80%                        ns                       ns                                                                     ns
  6                  Ruhwald et al. ([@B28])              2008                      Nigeria                              QFT-GIT             120                  48                       53                       19                            15.8%                      ns%                  ns                     0--15                 2005                        85.8%                      ns                       ns                                                                     ns
  7a                 Mandalakas et al. ([@B29])           2008                      South Africa                         QFT Gold            12                   2                        10                       0                             0%                         4.4%                 ns                     ns                    2005--2006                  ns                         100%                     ns                                                                     ns
  7b                 Mandalakas. ([@B29])                 2008                      South Africa                         T-SPOT.TB           23                   12                       11                       0                             0%                         4.4%                 ns                     ns                    2005--2006                  91.3%                      100%                     ns                                                                     ns
  8                  Ohno et al. ([@B30])                 2008                      Japan                                QFT Gold            17                   0                        17                       0                             0%                         ns%                  ns                     0--10                 2006                        35.3%                      ns                       ns                                                                     ns
  9                  Soysal et al. ([@B31])               2008                      Turkey                               T-SPOT.TB           209                  31                       173                      5                             2.4%                       8.4%                 ns                     6--10                 2006                        90%                        ns                       ns                                                                     ns
  10                 Chun et al. ([@B32])                 2008                      South Korea                          QFT-GIT             227                  16                       194                      17                            7.5%                       ns%                  3.2                    0--15.7               2006--2007                  99.6%                      0%                       ns                                                                     ns
  11a                Connell et al. ([@B33])              2008                      Australia                            QFT-GIT             96                   28                       65                       3                             3.1%                       8.9%                 ns                     0.5--19               ns                          52.1%                      0%                       ns                                                                     ns
  11b                Connell et al. ([@B33])              2008                      Australia                            T-SPOT.TB           96                   25                       57                       14                            14.6%                      8.9%                 ns                     0.5--19               ns                          52.1%                      0%                       ns                                                                     ns
  12                 Petrucci et al. ([@B34])             2008                      Nepal, Brasil                        QFT-GIT             259                  117                      136                      6                             2.3%                       8.5%                 ns                     0.2--15               ns                          96.5%                      ns                       ns                                                                     ns
  13a                Richeldi et al. ([@B35])             2008                      Italy                                QFT Gold            70                   9                        51                       10                            14.3%                      6.1%                 ns                     ns                    ns                          ns                         ns                       ns                                                                     ns
  13b                Richeldi et al ([@B35])              2008                      Italy                                QFT-GIT             81                   8                        63                       10                            12.3%                      6.9%                 ns                     ns                    ns                          ns                         ns                       ns                                                                     ns
  14                 Bianchi et al. ([@B36])              2009                      Italy                                QFT-GIT             336                  60                       274                      2                             0.6%                       ns%                  4.5                    2.6--6.8              2005--2006                  51.5%                      ns                       ns                                                                     ns
  15a                Hesseling et al. ([@B37])            2009                      South Africa                         QFT Gold            21                   8                        10                       3                             14.3%                      2.9%                 ns                     0--5                  2005--2006                  100%                       0%                       ns                                                                     ns
  15b                Hesseling et al. ([@B37])            2009                      South Africa                         T-SPOT.TB           28                   25                       2                        1                             3.6%                       2.9%                 ns                     0--5                  2005--2006                  100%                       0%                       ns                                                                     ns
  16                 Higuchi et al. ([@B38])              2009                      Japan                                QFT                 308                  6                        300                      2                             0.6%                       9.2%                 ns                     8--12                 2005--2006                  99%                        ns                       ns                                                                     ns
  17                 Kobashi et al. ([@B39])              2009                      Japan                                QFT-2G              25                   20                       2                        3                             12%                        ns%                  ns                     0--19                 2005--2008                  52%                        0%                       Immunosuppressive treatment                                            4%
  18a                Kampmann et al. ([@B40])             2009                      UK                                   QFT-GIT             209                  80                       115                      14                            6.7%                       8%                   ns                     0.2--16               2006--2008                  67.9%                      ns                       ns                                                                     ns
  18b                Kampmann et al. ([@B40])             2009                      UK                                   T-SPOT.TB           206                  70                       118                      18                            8.7%                       8%                   ns                     0.2--16               2006--2008                  67.9%                      ns                       ns                                                                     ns
  19                 Haustein et al. ([@B16])             2009                      UK                                   QFT Gold            237                  41                       113                      83                            35%                        ns%                  7.3                    0--18                 2006--2008                  50.6%                      0.8%                     Inflammatory disorder, organ transplantation, asplenia, malignancies   24.1%
  20a                ruzzese et al. ([@B41])              2009                      Italy                                QFT-GIT             80                   1                        63                       16                            20%                        12.5%                ns                     2--24                 ns                          0%                         0%                       Rheumatoid arthritis, liver transplantation, panarteritis              100%
  20b                Bruzzese et al. ([@B41])             2009                      Italy                                T-SPOT.TB           74                   7                        57                       10                            13.5%                      12.5%                ns                     2--24                 ns                          0%                         0%                       Rheumatoid arthritis, liver transplantation, panarteritis              100%
  21                 Lighter et al. ([@B42])              2009                      USA                                  QFT-GIT             207                  31                       173                      3                             1.4%                       9%                   ns                     0.1--18               ns                          35.7%                      ns                       ns                                                                     ns
  22                 Stavri et al. ([@B43])               2009                      Romania                              QFT                 36                   17                       10                       9                             25%                        ns%                  ns                     12--18                ns                          100%                       100%                     ns                                                                     ns
  23a                Bamford et al. ([@B44])              2010                      UK                                   QFT-GIT             170                  101                      56                       13                            7.6%                       8.5                  ns                     0.2--16               2005--2007                  ns                         ns                       ns                                                                     ns
  23b                Bamford et al. ([@B44])              2010                      UK                                   T-SPOT.TB           94                   47                       47                       0                             0%                         8.5                  ns                     0.2--16               2005--2007                  ns                         ns                       ns                                                                     ns
  24                 Soborg et al. ([@B45])               2010                      Greenland                            QFT Gold            2117                 197                      1898                     22                            1%                         11.4                 ns                     0--18                 2005--2007                  21.7%                      ns                       ns                                                                     ns
  25                 Grare et al. ([@B46])                2010                      France                               QFT-GIT             51                   5                        39                       7                             13.7%                      6                    ns                     0.3--18               2007--2008                  41.2%                      0%                       ns                                                                     ns
  26a                Lucas et al. ([@B47])                2010                      Australia                            QFT-GIT             460                  45                       345                      70                            15.2%                      ns                   ns                     0.4--16               2007--2008                  70%                        0%                       Schistosomiasis, Malaria, Hepatitis, Strongyloides                     ns
  26b                Lucas et al. ([@B47])                2010                      Australia                            T-SPOT.TB           420                  38                       374                      8                             1.9%                       ns                   ns                     0.4--16               2007--2008                  70%                        0%                       Schistosomiasis, Malaria, Hepatitis, Strongyloides                     ns
  27a                Stefan et al. ([@B48])               2010                      South Africa                         QFT-GIT             34                   3                        26                       5                             14.7%                      ns                   7                      0.2--15               2007--2008                  100%                       0%                       Cancer                                                                 100%
  27b                Stefan et al. ([@B48])               2010                      South Africa                         T-SPOT.TB           27                   6                        17                       4                             14.8%                      ns                   7                      0.2--15               2007--2008                  100%                       0%                       Cancer                                                                 100%
  28                 Tsolia et al. ([@B49])               2010                      Greece                               QFT-GIT             286                  125                      152                      9                             3.1%                       ns                   ns                     0--15                 2007--2008                  ns                         ns                       ns                                                                     ns
  29                 Thomas et al. ([@B20])               2010                      Bangladesh                           QFT-GIT             302                  107                      121                      74                            24.5%                      13.1                 ns                     11--15.3              2009                        79.1%                      ns                       Helminth infection and malnutrition                                    83.1%
  30a                Adetifa et al. ([@B50])              2010                      Gambia                               QFT-GIT             215                  72                       141                      2                             0.9%                       ns                   ns                     0.5--14               ns                          59.1%                      1.4%                     ns                                                                     ns
  30b                Adetifa et al. ([@B50])              2010                      Gambia                               T-SPOT.TB           215                  71                       144                      0                             0%                         ns                   ns                     0.5--14               ns                          59.1%                      1.4%                     ns                                                                     ns
  31                 Kabeer et al. ([@B51])               2010                      India                                QFT-GIT             83                   2                        81                       0                             0%                         ns                   ns                     0--15                 ns                          74.7%                      0%                       ns                                                                     ns
  32                 Stavri et al. ([@B52])               2010                      Romania                              QFT Gold            60                   27                       15                       18                            30%                        9.44                 ns                     1--18                 ns                          100%                       ns                       ns                                                                     ns
  33a                Altet-Gómez, et al. ([@B53])         2011                      Spain                                QFT-GIT             166                  61                       105                      0                             0%                         9.1                  ns                     0--15                 2005--2007                  69.9%                      ns                       ns                                                                     ns
  33b                Altet-Gómez et al. ([@B53])          2011                      Spain                                T-SPOT.TB           166                  64                       99                       3                             1.8%                       9.1                  ns                     0--15                 2005--2007                  69.9%                      ns                       ns                                                                     ns
  34                 Cruz et al. ([@B54])                 2011                      USA                                  T-SPOT.TB           215                  70                       135                      10                            4.7%                       8.6                  ns                     0.1--18               2005--2006                  36.3%                      0%                       ns                                                                     ns
  35                 Moyo et al. ([@B55])                 2011                      South Africa                         QFT-GIT             397                  68                       308                      21                            5.3%                       ns                   1.9                    0.7--2.9              2005--2008                  100%                       0.5%                     ns                                                                     ns
  36                 Banach et al. ([@B56])               2011                      USA                                  QFT Gold            6629                 290                      6203                     136                           2.1%                       ns                   ns                     0--19                 2006--2008                  ns                         ns                       ns                                                                     ns
  37                 Kasambira et al. ([@B57])            2011                      South Africa                         QFT-GIT             270                  79                       172                      19                            7%                         ns                   6                      0.5--16               2006--2009                  95.2%                      5.2%                     ns                                                                     ns
  38                 Losi et al. ([@B58])                 2011                      Italy                                QFT-GIT             235                  80                       152                      3                             1.3%                       ns                   ns                     ns                    2006--2008                  76.6%                      ns                       ns                                                                     ns
  39                 Shah et al. ([@B59])                 2011                      South Africa                         QFT-GIT             196                  62                       117                      17                            8.7%                       6                    ns                     0.5--16               2006--2009                  94.9%                      3.6%                     ns                                                                     ns
  40                 Maritsi et al ([@B60])               2011                      UK                                   QFT-GIT             23                   1                        20                       2                             8.7%                       ns                   8.9                    1.5--13               2007                        21.7%                      ns                       Autoimmune disease                                                     100%
  41                 Thomas et al. ([@B61])               2011                      UK                                   QFT-GIT             283                  29                       236                      18                            6.4%                       5.3                  ns                     0--16                 2007-2009                   71.7%                      ns                       ns                                                                     ns
  42                 Zrinski et al. ([@B62])              2011                      Croatia                              QFT-GIT             2173                 485                      1678                     10                            0.5%                       ns                   ns                     0.1--18               2007--2010                  100%                       ns                       ns                                                                     ns
  43                 Debord et al. ([@B63])               2011                      France                               QFT-GIT             19                   15                       4                        0                             0%                         ns                   1.52                   0.3--5.4              2008--2010                  84.2%                      0%                       ns                                                                     ns
  44                 Pavić et al. ([@B64])                2011                      Croatia                              QFT Gold            142                  18                       123                      1                             0.7%                       2.4                  ns                     0.1--5                2008--2009                  100%                       ns                       ns                                                                     ns
  45                 Mount et al. ([@B65])                2011                      UK                                   QFT Gold            126                  92                       29                       5                             4%                         6.2                  ns                     0.2--16.4             2009--2011                  99%                        ns                       ns                                                                     ns
  46                 Borgia et al. ([@B66])               2011                      Italy                                QFT GIT             1340                 118                      1219                     3                             0.2%                       ns                   ns                     0--0.25               2011                        ns                         ns                       ns                                                                     ns
  47                 Yassin et al. ([@B67])               2011                      Ethiopia                             QFT-GIT             737                  256                      308                      173                           23.5%                      ns                   ns                     1--15                 Ns                          72.5%                      7.1%                     ns                                                                     ns
  48                 Buonsenso et al. ([@B68])            2012                      Italy                                QFT Gold            66                   64                       1                        1                             1.5%                       ns                   ns                     0--16                 1990--2009                  ns                         3%                       ns                                                                     ns
  49                 Riazi et al. ([@B69])                2012                      USA                                  QFT-GIT             517                  27                       453                      37                            7.2%                       ns                   ns                     0.1--18               2004--2011                  68.7%                      ns                       ns                                                                     ns
  50                 Banfield et al. ([@B70])             2012                      Australia                            QFT Gold, QFT-GIT   573                  57                       423                      93                            16.2%                      ns                   ns                     0--17                 2006--2007                  ns                         0%                       Helminth infection                                                     40%
  51a                Basu Roy et al. ([@B71])             2012                      Bulgaria, Greece, Italy, Spain, UK   QFT-GIT             1093                 331                      742                      20                            1.8%                       8.2                  ns                     0--16                 2006--2009                  61.7%                      ns                       ns                                                                     ns
  51b                Basu Roy et al. ([@B71])             2012                      Bulgaria, Greece, Italy, Spain, UK   T-SPOT.TB           382                  145                      231                      6                             1.6%                       8.2                  ns                     0--16                 2006--2009                  61.7%                      ns                       ns                                                                     ns
  52                 Critselis et al. ([@B72])            2012                      Greece                               QFT-GIT             761                  221                      517                      23                            3%                         7.84                 ns                     0--18                 2007--2010                  45.2%                      ns                       ns                                                                     ns
  53                 Mendez-Echevarria et al. ([@B73])    2012                      Spain                                QFT-GIT             459                  96                       343                      20                            4.4%                       4.73                 ns                     0.1--15               2007--2009                  46.4%                      ns                       ns                                                                     ns
  54                 Pong et al. ([@B74])                 2012                      USA                                  QFT-GIT             23                   22                       0                        1                             4.3%                       8.5                  ns                     0--16                 2007--2010                  ns                         ns                       ns                                                                     ns
  55                 Nenadic et al. ([@B75])              2012                      Croatia                              QFT-GIT             59                   57                       2                        0                             0%                         12                   ns                     4--18                 2008--2009                  100%                       ns                       ns                                                                     ns
  56                 Onur et al. ([@B76])                 2012                      Turkey                               QFT-GIT             97                   37                       54                       6                             6.2%                       ns                   ns                     0.2--14               2008--2009                  87.6%                      ns                       ns                                                                     ns
  57                 Rose et al. ([@B77])                 2012                      Tanzania                             QFT                 211                  26                       128                      57                            27%                        ns                   ns                     0--15                 2008--2010                  91%                        37%                      ns                                                                     ns
  58                 Kabeer et al. ([@B78])               2012                      India                                QFT-GIT             145                  32                       113                      0                             0%                         ns                   ns                     0--17                 2008--2009                  ns                         ns                       ns                                                                     ns
  59                 Tuuminen et al. ([@B79])             2012                      Finland                              QFT-GIT             59                   2                        56                       1                             1.7%                       ns                   12                     11--14                2008                        ns                         ns                       ns                                                                     ns
  60                 Ling et al. ([@B80])                 2012                      Canada                               QFT-GIT             399                  82                       311                      6                             1.5%                       ns                   13                     0--18                 2009--2011                  82%                        ns                       ns                                                                     ns
  61                 Nkurunungi et al. ([@B81])           2012                      Uganda                               T-SPOT.TB           907                  88                       770                      49                            5.4%                       5                    ns                     5                     2009--2011                  100%                       1.4%                     Helminth infection                                                     9%
  62                 Verhagen et al. ([@B82])             2012                      Venezuela                            QFT-GIT             140                  48                       80                       12                            8.6%                       8.15                 ns                     1--15                 2010--2011                  86.4%                      ns                       Parasitic infection                                                    97.1%
  63                 Dayal et al. ([@B83])                2012                      India                                QFT-GIT             150                  64                       57                       29                            19.3%                      ns                   ns                     0--18                 ns                          52%                        ns                       ns                                                                     ns
  64                 Rutherford et al. ([@B84])           2012                      Indonesia                            QFT-GIT             371                  171                      190                      10                            2.7%                       ns                   5.1                    0.2--10               ns                          73.3%                      ns                       ns                                                                     ns
  65                 Blandinières et al. ([@B85])         2013                      France                               QFT-GIT             226                  53                       150                      23                            10.2%                      ns                   ns                     0--15                 2007--2011                  31.9%                      ns                       ns                                                                     ns
  66a                Mandalakas et al. ([@B86])           2013                      South Africa                         QFT-GIT             238                  57                       171                      10                            4.2%                       ns                   3.25                   0.2--14.6             2007-2010                   93%                        50.8%                    ns                                                                     ns
  66b                Mandalakas et al. ([@B86])           2013                      South Africa                         T-SPOT.TB           228                  47                       180                      1                             0.4%                       ns                   3.25                   0.2--14.6             2007--2010                  93%                        50%                      ns                                                                     ns
  67                 Yassin et al. ([@B87])               2013                      Ethiopia                             QFT-GIT             458                  158                      223                      77                            16.8%                      ns                   ns                     1--15                 2007--2009                  75.8%                      5.9%                     ns                                                                     ns
  68                 Chegou et al. ([@B88])               2013                      South Africa                         QFT-GIT             76                   41                       33                       2                             2.6%                       3.1                  ns                     0--13                 2008                        90%                        28.9%                    ns                                                                     ns
  69                 Rose et al. ([@B89])                 2013                      Tanzania                             QFT-GIT             152                  20                       93                       39                            25.7%                      4.2                  ns                     0--15                 2008--2010                  95.4%                      35.5%                    ns                                                                     ns
  70                 Bua et al. ([@B90])                  2013                      Italy                                QFT-GIT             105                  21                       84                       0                             0%                         ns                   ns                     0.2--15               2009--2011                  1.9%                       0%                       ns                                                                     ns
  71a                Carvalho et al. ([@B91])             2013                      Italy                                QFT-GIT             18                   0                        15                       3                             16.7%                      ns                   5.5                    1--18                 2009--2010                  ns                         0%                       Cancer                                                                 100%
  71b                Carvalho et al. ([@B91])             2013                      Italy                                T-SPOT.TB           17                   2                        12                       3                             17.6%                      ns                   6                      1--18                 2009-2010                   ns                         0%                       Cancer                                                                 100%
  72                 Ling et al. ([@B92])                 2013                      South Africa                         T-SPOT.TB           557                  175                      353                      29                            5.2%                       ns                   1.9                    0--15                 2009-2011                   80.3%                      22.3%                    ns                                                                     ns
  73                 Uluk et al. ([@B93])                 2013                      Papua New Guinea                     QFT-GIT             199                  68                       122                      9                             4.5%                       ns                   ns                     0.1--12               2009--2010                  75%                        12.5%                    ns                                                                     ns
  74                 Wassie et al. ([@B94])               2013                      Ethiopia                             QFT-GIT             245                  51                       187                      7                             2.9%                       14.8                 15                     12--20                2009                        100%                       0%                       Helminth infection                                                     20%
  75                 Laniado-Laborin et al. ([@B95])      2013                      Mexico                               QFT-GIT             173                  71                       101                      1                             0.6%                       7.6                  ns                     0--16                 2011--2013                  95.3%                      ns                       ns                                                                     ns
  76                 Dhanasekaran et al. ([@B96])         2013                      India                                QFT-GIT             210                  40                       166                      4                             1.9%                       ns                   ns                     0--3                  ns                          100%                       ns                       ns                                                                     ns
  77                 Lodha et al. ([@B97])                2013                      India                                QFT-GIT             362                  297                      58                       7                             1.9%                       ns                   9.6                    0.5--15               ns                          74%                        0%                       ns                                                                     ns
  78                 Cranmer et al. ([@B98])              2014                      Kenya                                T-SPOT.TB           160                  14                       114                      32                            20%                        ns                   ns                     0--0.5                1999--2002                  100%                       7%                       ns                                                                     ns
  79                 Garazzino et al. ([@B99])            2014                      Italy                                QFT-GIT             823                  126                      662                      35                            4.3%                       1.1                  1.1                    0--2                  2005--2012                  26.5%                      ns                       ns                                                                     ns
  80                 Hermansen et al. ([@B100])           2014                      Denmark                              QFT-GIT             28                   26                       1                        1                             3.6%                       ns                   ns                     1--14                 2005--2010                  ns                         ns                       ns                                                                     ns
  81                 Jenum et al. ([@B101])               2014                      India                                QFT-GIT             691                  36                       633                      22                            3.2%                       1.2                  ns                     0.1--2.9              2007--2010                  100%                       ns                       ns                                                                     ns
  82                 Holm et al. ([@B102])                2014                      Tanzania                             QFT-GIT             203                  26                       124                      53                            26.1%                      ns                   3                      0--15                 2008--2010                  ns                         37.4%                    ns                                                                     ns
  83                 Song et al. ([@B103])                2014                      South Korea                          QFT-GIT             2982                 317                      2649                     16                            0.5%                       15.1                 ns                     11--19                2008--2012                  61%                        ns                       ns                                                                     ns
  84                 Vallada et al. ([@B104])             2014                      Brasil                               QFT-GIT             195                  10                       179                      6                             3.1%                       3.9                  ns                     0.2--5.9              2008                        100%                       ns                       ns                                                                     ns
  85                 Pérez-Porcuna et al. ([@B105])       2014                      Brasil                               QFT-GIT             135                  36                       80                       19                            14.1%                      ns                   3.8                    0--6                  2009--2010                  87.4%                      ns                       Helminth infection                                                     22.2%
  86a                Tieu et al. ([@B106])                2014                      Thailand                             QFT-GIT             157                  51                       106                      0                             0%                         7.2                  ns                     0.2--16               2009-2011                   97.5%                      1.9%                     ns                                                                     ns
  86b                Tieu et al. ([@B106])                2014                      Thailand                             T-SPOT.TB           157                  47                       110                      0                             0%                         7.2                  ns                     0.2--16               2009--2011                  97.5%                      1.9%                     ns                                                                     ns
  87                 Bui et al. ([@B107])                 2014                      USA                                  QFT-GIT             183                  12                       115                      56                            30.6%                      11                   ns                     0--18                 2010--2011                  ns                         15.8%                    Cancer, autoimmune disease, inflammatory bowel disease                 41%
  88a                Chiappini et al. ([@B108])           2014                      Italy                                QFT-GIT             332                  96                       236                      0                             0%                         ns                   5.5                    ns                    2010--2013                  33%                        ns                       ns                                                                     ns
  88b                Chiappini et al. ([@B108])           2014                      Italy                                T-SPOT.TB           313                  70                       234                      9                             2.9%                       ns                   5.5                    ns                    2010--2013                  33%                        ns                       ns                                                                     ns
  89                 Rose et al. ([@B109])                2014                      Canada                               QFT-GIT             81                   15                       65                       1                             1.2%                       12.5                 ns                     0-18                  2010--2011                  32.1%                      100%                     ns                                                                     ns
  90                 Verhagen et al. ([@B110])            2014                      Venezuela                            QFT-GIT             151                  63                       77                       11                            7.3%                       7.7                  ns                     0-16                  2010--2011                  86.8%                      0%                       ns                                                                     ns
  91                 Tebruegge et al. ([@B15])            2014                      UK                                   QFT-GIT             263                  ns                       ns                       24                            9.1%                       ns                   ns                     0-18                  2011--2013                  ns                         ns                       Immunosuppressive therapy                                              3.1%
  92                 Al Mekaini et al. ([@B111])          2014                      Abu Dhabi                            QFT-GIT             666                  4                        660                      2                             0.3%                       ns                   8.7                    1--19                 2013                        71.6%                      ns                       ns                                                                     ns
  93a                de Souza-Galvao et al. ([@B112])     2014                      Spain                                QFT-GIT             37                   23                       14                       0                             0%                         9.2                  ns                     ns                    ns                          67.6%                      0%                       ns                                                                     ns
  93b                de Souza-Galvao et al. ([@B112])     2014                      Spain                                T-SPOT.TB           37                   21                       16                       0                             0%                         9.2                  ns                     ns                    ns                          67.6%                      0%                       ns                                                                     ns
  94                 Calzada-Hernandez et al. ([@B113])   2015                      Spain                                QFT-GIT             75                   3                        66                       6                             8%                         ns                   ns                     0--18                 2004--2013                  ns                         ns                       Autoimmune disease                                                     100%
  95                 Caliman-Sturdza et al. ([@B114])     2015                      Romania                              QFT-GIT             125                  52                       64                       9                             7.2%                       10.45                ns                     0.7--17               2006--2010                  64.8%                      12.8%                    Diabetes, leukemia                                                     2.4%
  96                 Sali et al. ([@B115])                2015                      Italy                                QFT-GIT             621                  59                       536                      26                            4.2%                       4.1                  ns                     0--14                 2007--2010                  ns                         0.2%                     Leukemia, juvenile arthritis, Evan\'s syndrome                         1%
  97a                Mandalakas et al. ([@B116])          2015                      South Africa                         QFT-GIT             1295                 520                      741                      34                            2.6%                       ns                   4.9                    0.2--15               2008--2012                  86.7%                      22%                      ns                                                                     ns
  97b                Mandalakas et al. ([@B116])          2015                      South Africa                         T-SPOT.TB           1243                 302                      939                      2                             0.2%                       ns                   4.9                    0.2--15               2008--2012                  86.7%                      21.4%                    ns                                                                     ns
  98                 Spicer et al. ([@B117])              2015                      USA                                  T-SPOT.TB           107                  5                        91                       11                            10.3%                      3.3                  1.9                    0.3--16               2008--2011                  73.8%                      0%                       ns                                                                     ns
  99                 Bao et al. ([@B118])                 2015                      China                                QFT-GIT             57                   28                       28                       1                             1.8%                       4.3                  ns                     0--16                 2010--2011                  ns                         0%                       Patients on glucocorticoid therapy                                     21.1%
  100                Howley et al. ([@B119])              2015                      USA                                  QFT-GIT             2520                 142                      2365                     13                            0.5%                       ns                   ns                     2--14                 2010--2011                  ns                         ns                       ns                                                                     ns
  101                Pavic et al. ([@B120])               2015                      Croatia                              QFT-GIT             171                  26                       143                      2                             1.2%                       2.4                  ns                     0.1--5                2010--2012                  98.8%                      ns                       ns                                                                     ns
  102                Tebruegge et al. ([@B121])           2015                      Australia                            QFT-GIT             142                  22                       103                      2                             1.4%                       ns                   8.3                    0--18                 2010--2011                  47.2%                      ns                       ns                                                                     ns
  103                Lebina et al. ([@B122])              2015                      South Africa                         QFT-GIT             2105                 351                      1744                     10                            0.5%                       ns                   ns                     5--7                  2011                        ns                         ns                       ns                                                                     ns
  104                Petrone et al. ([@B123])             2015                      Uganda                               QFT-GIT             105                  17                       81                       7                             6.7%                       ns                   ns                     0--16                 2011--2012                  ns                         29.5%                    ns                                                                     ns
  105                Sun et al. ([@B124])                 2015                      China                                T-SPOT.TB           579                  119                      411                      49                            8.5%                       ns                   ns                     0--5                  2011--2014                  91%                        0%                       ns                                                                     ns
  106a               Li et al. ([@B125])                  2015                      China                                QFT-GIT             57                   28                       28                       1                             1.8%                       ns                   ns                     ns                    ns                          100%                       0%                       ns                                                                     ns
  106b               Li et al. ([@B125])                  2015                      China                                T-SPOT.TB           96                   46                       50                       0                             0%                         ns                   ns                     ns                    ns                          100%                       0%                       ns                                                                     ns
  107                Cruz et al. ([@B126])                2015                      Botswana                             QFT Gold            100                  1                        96                       3                             3%                         ns                   10.2                   0.8--17               ns                          92%                        100%                     ns                                                                     ns
  108                Grinsdale et al. ([@B127])           2016                      USA                                  QFT-GIT, QFT Gold   1092                 72                       943                      77                            7.1%                       ns                   8.7                    0--15                 2005--2008                  ns                         ns                       ns                                                                     ns
  109                Santiago-Garcia et al. ([@B128])     2016                      Spain                                QFT-GIT             81                   64                       11                       6                             7.4%                       ns                   ns                     0--18                 2005--2013                  ns                         ns                       ns                                                                     ns
  110                Perez-Porcuna et al. ([@B129])       2016                      Brasil                               QFT                 121                  34                       71                       16                            13.2%                      ns                   ns                     0--6                  2009--2010                  100%                       ns                       ns                                                                     ns
  111                Atikan et al. ([@B130])              2016                      Turkey                               QFT-GIT             71                   5                        65                       1                             1.4%                       8                    ns                     3.5--18               2010--2013                  97.2%                      ns                       Rheumatic disease                                                      100%
  112                Boddu et al. ([@B131])               2016                      India                                QFT-GIT             89                   21                       62                       6                             6.7%                       ns                   ns                     1--15                 2010--2011                  98.9%                      ns                       ns                                                                     ns
  113a               Nozawa et al. ([@B132])              2016                      Japan                                QFT-GIT             81                   4                        69                       8                             9.9%                       10.5                 ns                     1.1--19.2             2010--2014                  95.1%                      ns                       Rheumatic disease                                                      100%
  113b               Nozawa et al. ([@B132])              2016                      Japan                                T-SPOT.TB           27                   0                        27                       0                             0%                         10.15                ns                     3.3--19.8             2010--2014                  96.3%                      ns                       Rheumatic disease                                                      100%
  114                El Azbaoui et al. ([@B133])          2016                      Morocco                              QFT-GIT             109                  40                       49                       20                            18.3%                      7.8                  ns                     0.4--17               2011--2015                  100%                       0%                       ns                                                                     ns
  115                Yun et al. ([@B134])                 2016                      South Korea                          QFT-GIT             106                  15                       88                       3                             2.8%                       ns                   9                      0--18                 2011--2015                  99%                        ns                       ns                                                                     ns
  116                Beshir et al. ([@B135])              2016                      Egypt                                QFT-GIT             150                  5                        142                      3                             2%                         1.4                  0.75                   0--12                 2014--2015                  82%                        ns                       ns                                                                     ns
  117                Wong et al. ([@B136])                2017                      Taiwan                               QFT-GIT             47                   8                        36                       3                             6.4%                       10.2                 ns                     0.2--18               2008--2014                  100%                       ns                       Leukemia                                                               12.8%
  118                Gabriele et al. ([@B137])            2017                      Greece                               QFT-GIT             79                   3                        74                       2                             2.5%                       ns                   12                     ns                    2011--2012                  30.4%                      ns                       Juvenile arthritis, lupus                                              100%
  119                Mensah et al. ([@B138])              2017                      Ghana                                QFT-GIT             32                   20                       10                       2                             6.3%                       ns                   ns                     0--15                 2012--2014                  78.1%                      ns                       ns                                                                     ns
  120                Li et al. ([@B139])                  2017                      China                                QFT-GIT             2831                 71                       2698                     62                            2.2%                       9.6                  ns                     5--15                 2013                        64.2%                      0%                       ns                                                                     ns
  121                Petrucci et al. ([@B140])            2017                      Italy                                QFT-GIT             517                  79                       418                      20                            3.9%                       5.4                  ns                     0--14                 Ns                          9.7%                       ns                       ns                                                                     ns
  122                Silveira et al. ([@B141])            2018                      Brasil                               T-SPOT.TB           86                   21                       52                       13                            15.1%                      ns                   9.8                    0--19                 2007--2011                  83.7%                      16.3%                    Autoimmune disease, neoplasia, other immunodeficiencies                36.1%
  123                Bielecka et al. ([@B142])            2018                      Poland                               QFT-GIT             146                  17                       126                      3                             2.1%                       ns                   7.8                    0--17                 2009--2012                  99%                        0%                       Juvenile arthritis, ulcerative colitis                                 1.4%
  124                Chiappini et al. ([@B143])           2018                      Italy                                QFT-GIT             762                  32                       730                      0                             0%                         ns                   3.6                    0--18                 2009--2015                  53.9%                      0.1%                     Parasitic infection                                                    53.7%
  125                Mastrolia et al. ([@B144])           2018                      Italy                                QFT-GIT             1779                 86                       1689                     4                             0.2%                       ns                   5.8                    0--18                 2009--2017                  75.8%                      0%                       ns                                                                     ns
  126                Mandalakas et al. ([@B145])          2018                      USA, Puerto Rico                     T-SPOT.TB           43196                2189                     40753                    254                           0.6%                       ns                   12.5                   0--17                 2010--2015                  ns                         ns                       ns                                                                     ns
  127                Gaensbauer et al. ([@B146])          2018                      USA                                  QFT                 6336                 450                      5852                     34                            0.5%                       ns                   ns                     2--18                 2011--2014                  ns                         ns                       ns                                                                     ns
  128                Hormi et al. ([@B147])               2018                      France                               QFT                 63                   8                        51                       4                             6.3%                       ns                   11.6                   0.4--18               2011--2015                  92.1%                      100%                     ns                                                                     ns
  129a               Starshinova et al. ([@B148])         2018                      Russia                               QFT-GIT             312                  201                      111                      0                             0%                         ns                   ns                     1--19                 2011--2016                  100%                       0%                       ns                                                                     ns
  129b               Starshinova et al. ([@B148])         2018                      Russia                               T-SPOT.TB           236                  32                       204                      0                             0%                         ns                   ns                     1--19                 2011--2016                  100%                       0%                       ns                                                                     ns
  130                Sayyahfar et al. ([@B149])           2018                      Iran                                 QFT                 31                   0                        31                       0                             0%                         8.79                 ns                     3--15                 2013--2014                  100%                       ns                       Renal dysfunction                                                      100%
  131                Said et al. ([@B150])                2018                      Tanzania                             QFT Gold            301                  39                       244                      18                            6%                         ns                   2.2                    0.5--4.9              2015--2016                  100%                       1.3%                     Helminth infection                                                     22.3%
  132                Sali et al. ([@B151])                2018                      Italy                                QFT                 550                  64                       477                      9                             1.6%                       5.8                  ns                     0--14                 ns                          43.5%                      ns                       ns                                                                     ns
  133                Vortia et al. ([@B152])              2018                      USA                                  QFT-GIT             93                   2                        90                       1                             1.1%                       ns                   16                     5--19                 ns                          ns                         ns                       Inflammatory bowel disease                                             100%
  Total                                                                                                                                      107'418                                                                2555                                                                                                 0--24                 1999--2018                                                                                                                                             

*QFT, QuantiFERON-TB, assay generation not specified; QFT-GIT, QuantiFERON-TB Gold in tube; ns, not specified*.

The 155 datasets included a total of 107,418 participants with a median number of participants of 166 (range 12--43,196) per dataset. The mean or median age was specified in 69% (107/155) of datasets and reported to be 7.6 and 6 years, respectively. Upper age range was 18 years in 87.2% (116/133), 19 years in 5.3% (7/133), 24 years in 2.3% (3/133), and not specified in 5.3% (7/133) of studies. The studies were done in 45 countries with 36.8% (49/133) in Europe, 21.8% (29/133) in Asia, 20.3% (27/133) in Africa, 11.3% (15/133) in North America, 4.5% (6/133) in Australia, 4.5% (6/133) in South America, and 0.75% (1/133) recruited children in two continents (Asia and South America).

The BCG vaccination rates were reported in 80% (124/155) of datasets and varied from 0 to 100% with a median of 82%. HIV infection rates were reported in 49% (76/155) and varied from 0 to 100% with the median infection rate of 0.05%.

In 33 datasets additional information on immunocompromising or other factors potentially influencing IGRA results was reported: rheumatic or autoimmune diseases in 12.3% (19/155), various forms of cancer in 4.5% (7/155), and parasitic infections in 6.5% (10/155) of datasets. The range of participants included with additional factors varied from 1 to 100% with a median of 83.1% (not specified in 2 datasets).

Definition of Indeterminate Results of Interferon-Gamma Release Assays
----------------------------------------------------------------------

A definition for indeterminate results was included in 88% (117/133) of studies with definitions provided for QuantiFERON-TB in 85.7% (108/126) and for T-SPOT.TB in 96.7% (29/30) of datasets. Of those that included a definition for indeterminate results most datasets 49.7% (77/155) simply stated to have used the manufacturers\' definition \[QuantiFERON-TB 47.6% (60/126) and T-SPOT.TB 56.7% (17/30)\]. Further to this for the definition of indeterminate results in the QuantiFERON-TB assay three studies used their own definitions for failed nil controls \[nil tube interferon-γ concentration of \> 0.7 IU/ml ([@B56]) and \> 2.0 IU/ml ([@B63], [@B147]), respectively\]; five studies stated presence of high background response without reporting specific values ([@B23], [@B36], [@B47], [@B70], [@B74]).

Definition of indeterminate results for the T-SPOT.TB most commonly referred to low mitogen and/or high nil responses in combination with negative antigen response without stating specific values. Some studies indicated the absolute number of spots as cut-offs, others defined the number of spots in relation to the nil and/or mitogen response. In four studies a nil control of more than 10 spots was considered indeterminate, as opposed to the manufacturer\'s definition of ≥ 6 spots ([@B92], [@B98], [@B112], [@B145]).

Type of Interferon-Gamma Release Assays
---------------------------------------

Of the 133 studies, 77.4% (103/133) assessed QFT only, 15.8% (21/133) assessed both QuantiFERON-TB and T-SPOT.TB, and 6.8% (9/133) assessed T-SPOT.TB only. The proportions of indeterminate results ranged from 0 to 35% in the included studies. The overall pooled effect size (equivalent to the pooled proportion of indeterminate results) was 0.04 (95% CI 0.03--0.05, I^2^ = 96.32%) for both IGRAs combined.

QuantiFERON-TB was used in 124 studies including 57,183 participants. The pooled proportion of indeterminate results of QuantiFERON-TB was 0.05 (95% CI 0.04--0.06, I^2^ = 96.06%) ([Figure 2](#F2){ref-type="fig"}). T-SPOT.TB was analyzed in 30 studies including 50,235 participants. The pooled proportion of indeterminate results of T-SPOT.TB was 0.03 (95% CI 0.02--0.05, I^2^ = 95.02%).

![Proportion of indeterminate results with 95% CI by type of IGRA. Studies arranged according to year of publication.](fped-07-00208-g0002){#F2}

A total of 21 studies assessed QuantiFERON-TB and T-SPOT.TB in the same study which allowed calculation of risk differences for the proportion of indeterminate results. The pooled proportion of indeterminate results was lower for T-SPOT.TB compared to QuantiFERON-TB (risk difference −0.01, 95% CI −0.03 to −0.00, I^2^ = 87.7%), but did not reach statistical significance ([Figure 3](#F3){ref-type="fig"}).

![Risk difference (RD) with 95% CI in studies that included a head-to-head comparison of QuantiFERON-TB and T-SPOT.TB assays. Studies arranged according to year of publication.](fped-07-00208-g0003){#F3}

Indeterminate Results According to Age
--------------------------------------

The mean or median age was specified in 108 datasets; of those 55 datasets had median or mean ages 0--7 years 52 datasets had median or mean ages ≥8years. The pooled proportions of indeterminate results were 0.04 (95% CI 0.03--0.06, I^2^ = 94.46%) for the age group 0--7 years and 0.04 (95% CI 0.03--0.05, I^2^ = 95.19%) for ≥8years. For the 48 datasets in which the mean or median age was not specified the proportions of indeterminate results were 0.05 (95% CI 0.03--0.06, I^2^ = 97.35%).

Of the 21 studies comparing both QuantiFERON-TB and T-SPOT.TB, 16 studies specified mean or median age. The pooled risk difference (negative values indicating lower risk of indeterminate results in the T-SPOT.TB) for 0--7 years was −0.01 (95% CI −0.03 to −0.01, I^2^ = 79.6%) and for ≥8 years −0.01 (95% CI −0.04 to −0.02, I^2^ = 76.7%). For studies which did not specify mean or median age the pooled risk difference was −0.03 (95% CI −0.10 to −0.05, I^2^ = 98.5%) ([Figure 4](#F4){ref-type="fig"}). Risk differences within age groups for both assays were not statistically significant.

![Risk differences (RD) with 95% CI in studies that included a head-to-head comparison of QuantiFERON-TB and T-SPOT.TB assays stratified by age. Studies sorted according to year of publication.](fped-07-00208-g0004){#F4}

Indeterminate Results According to Geographical Location of the Study Population
--------------------------------------------------------------------------------

A stratified analysis according to continents showed the following proportions for indeterminate IGRA results: Europe 0.03 (95% CI 0.02--0.05, I^2^ = 93.49%), Africa 0.07 (95% CI 0.04--0.10, I^2^ = 97.02%), Australia 0.08 (95% CI 0.04--0.14, I^2^ = 94.33%), Asia 0.03 (95% CI 0.01--0.04, I^2^ = 93.12%), North America 0.03 (95% CI 0.02--0.05, I^2^ = 97.48%), South America 0.09 (95% CI 0.06--0.14, I^2^ = 77.03%). One report with study sites in Asia and South America was excluded from this particular analysis, as the data could not be separated according to site of recruitment ([@B34]).

When continent of the study was included in the risk differences analysis the proportion of indeterminate results for T-SPOT.TB was significantly lower compared to QuantiFERON-TB in studies performed in Africa only (*p* \< 0.001). The pooled risk difference for African studies was −0.022 (95% CI −0.032 to −0.011, I^2^ = 15.4%). Risk differences for studies performed on all other continents were not statistically significant ([Figures 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}).

![Risk differences (RD) with 95% CI in studies that included a head-to-head comparison of QuantiFERON-TB and T-SPOT.TB assays stratified by continent. Studies arranged according to year of publication.](fped-07-00208-g0005){#F5}

![Risk differences (RD) with 95% CI in studies that included a head-to-head comparison of QuantiFERON-TB and T-SPOT.TB assays stratified by African/Non-African origin of the study. Studies arranged according to year of publication.](fped-07-00208-g0006){#F6}

Indeterminate Results by Immune Status
--------------------------------------

The pooled proportion of indeterminate IGRA results for the 0% HIV^+^, 0 \< 51% HIV^+^, 51--100% HIV^+^, immunocompromised/HIV^−^ and no information were 0.03 (95% CI 0.02--0.05, I^2^ = 94.45%), 0.07 (95% CI 0.04--0.11, I^2^ = 97.70%), 0.03 (95% CI 0.01--0.05, I^2^ = 73.96%), 0.12 (95% CI 0.07--0.18, I^2^ = 47.12%), 0.03 (95% CI 0.03--0.04, I^2^ = 94.78%), respectively.

When immune status was included in the risk difference analysis of indeterminate results the T-SPOT.TB was associated with lower proportions of indeterminate results only in studies that included immunocompromised, HIV-uninfected participants: the pooled risk difference was −0.071(95% CI −0.133 to −0.010, I^2^ = 0.0%) and statistically significant (*p* = 0.022). The risk differences in the remaining groups were not statistically significant ([Figure 7](#F7){ref-type="fig"}).

![Risk differences (RD) with 95% CI in studies that included a head-to-head comparison of QuantiFERON-TB and T-SPOT.TB assays stratified by immune status. Studies arranged according to year of publication.](fped-07-00208-g0007){#F7}

Meta-Regression of Indeterminate Results
----------------------------------------

Of the four variables in the model (type of IGRA, age group, continent where study was performed, immune status), only studies including non-HIV-infected immunocompromised patients had a statistically significant contribution to the heterogeneity in the multiple regression model (*p* = 0.0003).

Discussion {#s4}
==========

Indeterminate IGRA results have been reported shortly after introduction of these tests in routine clinical use. Despite this, analysis of indeterminate IGRA results has commonly been neglected in the literature, with those results either having been excluded from previous systematic literature reviews or only having been included in very limited subgroup analyses ([@B11], [@B153], [@B154]). To our knowledge, this systematic review is the first to comprehensively analyse the occurrence of indeterminate IGRA results in children and adolescents. We found that 4% of IGRA results are indeterminate, suggesting that 1 in 25 tests will not produce a conclusive result. The main factor associated with indeterminate results identified in this meta-analysis was the presence of an immunocompromising condition other than HIV infection.

In our analysis T-SPOT.TB assays were associated with a similar risk of indeterminate results compared to various generations of QuantiFERON-TB tests. T-SPOT.TB assays require lymphocyte adjustment which may reduce the risk of an indeterminate result particularly in patients with reduced lymphocyte count, such as HIV infection or immunocompromising conditions associated with lymphopenia. This assumption is confirmed by results from a meta-analysis including studies in adult HIV-infected patients showing that low CD4 cell counts increased indeterminate rates of QuantiFERON-TB but not of T-SPOT.TB assays ([@B155]). Our results contrast with another earlier meta-analysis by Diel et al that reported fewer indeterminate results for QFT-GIT (2.1%) compared to T-SPOT.TB (3.8%) ([@B154]). The authors concluded that the more demanding laboratory work for the T-SPOT.TB was likely the reason for higher indeterminate rates. However, their analysis predominately included studies in adults, did not include random effects models, and only included studies published until 2009.

Immunocompromising conditions, including HIV infection, have been identified in earlier studies as a major contributing factor to indeterminate results ([@B16]). A study by Oni et al. showed that HIV infection in adults increased the risk of indeterminate results, either through low positive control responses or high interferon-γ background concentrations in the negative control ([@B156]). In another study by Mandalakas et al. indeterminate results were more frequent in children infected with HIV than in HIV-uninfected children ([@B116]). The previously reported lower sensitivity of QuantiFERON-TB assays in HIV-infected individuals may be linked to a higher rate of indeterminate results, as the difference between the assays was negligible in a study after exclusion of indeterminate results in one analysis ([@B157]). Diel et al. reported in their meta-analysis that the rates of indeterminate results for QuantiFERON-TB and T-SPOT.TB assays were higher in immunocompromised compared to immunocompetent individuals, with 6.1 and 4.4%, respectively ([@B154]).

Further factors have been shown to influence IGRA results, particularly chronic rheumatic or auto-inflammatory diseases ([@B158], [@B159]). IGRA performance depends on intact cellular Th1 responses. Helminth infections, which primarily induce Th2 responses, may alter cytokine production and thereby increase the rate of indeterminate results ([@B20], [@B150], [@B160], [@B161]).

Importantly, in our analysis younger age was not associated with indeterminate results, reflected in similar proportions of indeterminate IGRA results in all age groups. This conflicts with several studies that have reported a clear correlation between IGRA performance, proportions of indeterminate results and age ([@B15], [@B16], [@B18], [@B27], [@B33], [@B158]). It is well-established that young children have a maturing immune system that may result in diminished cytokine release ([@B162], [@B163]). The link between age and cytokine concentrations has also been shown in numerous studies in healthy children unrelated to TB diagnostics ([@B162], [@B163]). One potential reason for not detecting a significant association between age and indeterminate IGRA results in this meta-analysis is that aggregate data based on the reported mean/median ages rather than individual patient data were used for this analysis.

There were several factors we were unable to analyse in the datasets that have been reported in some of the included studies, which mainly concern pre-analytical factors. Several studies in children and in adults found a decrease in interferon-γ production and indeterminate IGRA results to be associated with delayed sample incubation, shipping of samples, variation in environmental temperatures, and poor phlebotomy technique ([@B164]--[@B168]). In addition, co-medication may influence results as a recent *ex vivo* study showed that both corticosteroids and anti-TNF-alpha agents can cause false-negative IGRA results, and potentially also increase the rate of indeterminate results ([@B169]).

One potential limitation of our meta-analysis is the considerable heterogeneity of the included studies. Despite using empirical random effects weighting, excluding studies with \< 10 participants, and using only data of the two commercially available IGRAs, heterogeneity remained. Moreover, it is possible that studies with poor IGRA performance and higher proportion of indeterminate results were less likely to be published, leading to publication bias. In addition, details on the type of QuantiFERON-TB assays used were often not reported in the publications, precluding a comparison of different test generations.

Conclusions {#s5}
===========

In children, indeterminate IGRA results occur in 1 in 25 tests performed on average. Overall, there was no difference in the proportion of indeterminate results between both commercial assays. However, the data of this meta-analysis indicate that in patients in Africa and/or children with immunocompromising conditions other than HIV infection the T-SPOT.TB assay appears to produce fewer indeterminate results than the QuantiFERON-TB assays.
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BCG

:   Bacille Calmette-Guérin

CI

:   Confidence interval

HIV

:   Human immunodeficiency virus

IGRA

:   Interferon-gamma release assay

IFN-γ

:   Interferon-gamma

ns

:   not specified

QFT

:   QuantiFERON-TB

TB

:   Tuberculosis

TST

:   Tuberculin skin test. ^\*^QFT used representative for the two reported generations of QFT \[QFT Gold and QFT-GIT (Gold In-Tube)\].
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